Twitter Facebook LinkedIn

Our Members

Pfizer

About At Pfizer, we are driven by our desire to improve global public health and are encouraged to see the collective progress the industry is making to help curb the growing threat of AMR. We are pleased to have been recognized as the joint leader of pharmaceutical companies in the infectious disease market by the Access to Medicine Foundation’s 2022 Antimicrobial Resistance (AMR) Benchmark Report, based on the scope of our efforts to address AMR, our leadership in Stewardship, and our expanded R&D pipeline. Pfizer’s ATLAS surveillance program, which provides public access to raw data on antibiotic and antifungal resistance, is one of the largest surveillance platforms in the world.
How we share on the AMR Register To obtain Pfizer’s AMR surveillance data for analysis, researchers should use the AMR Register platform to submit a request. The de-identified data will then be made available to the researcher to download based on their selection criteria. Data for ongoing surveillance programs will be updated annually.
Programs Listed for Sharing Pfizer’s AMR surveillance data available on the AMR Register:
• ATLAS (Antimicrobial Testing Leadership and Surveillance)
What information will be provided Where available, the following data and information is provided for each dataset:
🗹 Raw dataset. This is the dataset containing the anonymized isolate level data collected during the study. The dataset can be downloaded.
🗹 Program description. Information about how the data were collected is provided on the program pages.
🗹 Links to Publications. Links to journal publications based on the data collected are provided on the program pages.
Data Request Review Process Researchers can request access to Pfizer’s datasets by providing a brief statement summarizing the goals and objectives of the proposed research. The research proposal is reviewed by Vivli and Pfizer.
Review Criteria for Data Requests All research proposals include a statement on how the research will improve patient outcomes, strengthen stewardship, and/or inform public health practice and health systems strengthening. If these criteria are not met Pfizer may decline the data request and inform the researcher accordingly.
Questions or enquiries Please send any questions or enquiries to amr@vivli.org
Pfizer’s Register or Website www.atlas-surveillance.com